Gland Pharma Ltd
NSE: GLAND BSE: 543245
₹1780.80
(-1.94%)
Sat, 14 Feb 2026, 07:07 pm
Market Cap293.21B
PE Ratio34.63
Dividend1.01
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1978
- The company was incorporated as Gland Pharma Private Limited
1994
- The name of the company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders
1995
- A fresh certificate of incorporation was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company
2000
- The company set up the in-house R&D facility at Dundigal, Hyderabad
2003
- The company received USFDA approval for the manufacturing facility at Dundigal
2005
- The company launched Enoxaparin Sodium Injection (Cutenox) in India and Rest of the world markets
2007
- The company received a capital infusion of approximately 1,000 million into the Company pursuant to private equity investment aggregating to approximately 1,200 million with EILSF Co-Invest I LLC
2010
- The company launched Heparin Sodium Injection in the US
2012
- The company received the Certificate of GMP Compliance of a Manufacturer from BGV Hamburg (Germany) for its manufacturing facility at Dundigal
2014
- The company obtained USFDA approval for small volume parenteral manufacturing facility at Visakhapatnam
- The company commissioned the Pashamylaram Unit-II manufacturing facility
- The company received the Certificate of GMP Compliance of a Manufacturer from MHRA (UK) for manufacturing facility at Dundigal
- The company received a capital infusion of US$ 100 million into the Company pursuant to private equity investment aggregating to approximately US$ 200 million with KKR Floorline Investment Pte Ltd
2016
- The company obtained USFDA approval for its facilities at Jawaharlal Nehru Pharma City, Visakhapatnam
- The company obtained USFDA approval for its manufacturing facility at Pashamylaram
- The company obtained USFDA approval for its facility at the Visakhapatnam Special Economic Zone
2017
- Fosun Singapore acquired 74% stake in the company
2018
- The company received ANDA approval for Enoxaparin Sodium Injection USP for the US market
- The company received ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%, its first Ophthalmic product approval
2019
- The company filed Dexrazoxane for Injection, its first filing with the National Medical Products Administration, China, and received clinical waiver
2020
- Gland Pharma along with its partners MAIA Pharmaceuticals, Inc. and Athenex Pharmaceutical Division announce the launch of a Ready-to-Use Bivalirudin Injection in the United States of America
2021
- Gland Pharma received approval for generic Foscarnet Sodium Injection, Single-Dose Bag for Infusion
- Gland Pharma receives Tentative Approval for Sugammadex Injection
- Gland Pharma receives tentative approval for Cangrelor injection
2022
- Gland Pharma enters into put option agreement to acquire 100% of Cenexi Group
- Gland Pharma announces launch of Bortezomib for Injection in US market
2024
- The Company received approval from the United States Food and Drug Administration (US FDA) for Plerixafor Injection
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800